Chromogranin A (CgA) serum level as a marker of progression in hepatocellular carcinoma (HCC) of elderly patients

Archives of Gerontology and Geriatrics

Volumn 51, Issue 1, 2010, Pages 81-85

  Malaguarnera, Michele ^a   Vacante, Marco ^a   Fichera, Rosangela ^a   Cappellani, Alessandro ^a   Cristaldi, Erika ^a   Motta, Massimo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Fetoprotein; Chromogranin A; Des carboxyl prothrombin; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; CHROMOGRANIN A; DECARBOXYPROTHROMBIN;

AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GERIATRIC PATIENT; HEPATITIS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TUMOR DIFFERENTIATION;

AGED; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHROMOGRANIN A; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; NEOPLASM STAGING;

EID: 77953322191     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2009.08.004     Document Type: Article

References (42)

1. Billingsley K.G., Jarnagin W.R., Fong Y., Blumgart L.H. Segment-oriented hepatic resection in the management of malignant neoplasms of the liver. J. Am. Coll. Surg. 1998, 187:471-481.
2. Bonkhoff H., Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996, 28:98-106.
3. Bruix J., Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
4. Cedrone A., Covino M., Caturelli E., Pompili M., Lorenzelli G., Villani M.R., Valle D., Sperandeo M., Rapaccini G.L., Gasbarrini G. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Hepatogastroenterology 2000, 47:1654-1658.
5. Deftos L.J. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr. Rev. 1991, 12:181-187.
6. Ebara M., Ohto M., Watanabe Y., Kimura K., Saisho H., Tsuchiya Y., Okuda K., Arimizu N., Kondo F., Ikehira H., Fukuda N., Tateno Y. Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histologic studies. Radiology 1986, 159:371-377.
7. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:S27-S34.
8. Hsiao R.J., Parmer R.J., Takiyyuddin M.A., O'Connor D.T. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine 1991, 70:33-45.
9. Iacangelo A.L., Eiden L.E. Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul. Pept. 1995, 58:65-88.
10. Ishak K.G. New developments in diagnostic liver pathology. Monogr. Pathol. 1987, 28:223-373.
11. Kouroumalis E.A. Octreotide for cancer of the liver and biliary tree. Chemotherapy 2001, 47:150-161.
12. Landsberg L. Chromogranin A. N. Engl. J. Med. 1984, 311:794-795.
13. Malaguarnera M., Cristaldi E., Cammalleri L., Colonna V., Lipari H., Capici A., Cavallaro A., Berretta M., Alessandria I., Luca S., Motta M. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Arch. Gerontol. Geriatr. 2009, 48:213-217.
14. Nguyen M.H., Garcia R.T., Simpson P.W., Wright T.L., Keeffe E.B. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002, 36:410-417.
15. Nobles F.R., Kwekkeboom D.J., Coopmans W., Schoenmakers C.H., Lindemans J., De Herder W.W., Krenning E.P., Bouillon R., Lamberts S.W. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J. Clin. Endocrinol. Metab. 1997, 82:2622-2628.
16. Nobles F.R., Kwekkeboom D.J., Bouillon R., Lamberts S.W. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur. J. Clin. Invest. 1998, 28:431-440.
17. O'Connor D.T., Deftos L.J. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N. Engl. J. Med. 1986, 314:1145-1151.
18. Okuda H., Nakanishi T., Takatsu K., Saito A., Hayashi N., Watanabe K., Magario N., Yokoo T., Naraki T. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 1999, 85:812-818.
19. Okuda H., Nakanishi T., Takatsu K., Saito A., Hayashi N., Yamamoto M., Takasaki K., Nakano M. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone. J. Gastroenterol. Hepatol. 2001, 16:1290-1296.
20. Peracchi M., Gebbia C., Basilisco G., Quatrini M., Tarantino C., Vescarelli C., Massironi S., Conte D. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur. J. Endocrinol. 2005, 152:443-448.
21. Poon T.C., Mok T.S., Chan A.T., Chan C.M., Leong V., Tsui S.H., Leung T.W., Wong H.T., Ho S.K., Johnson P.J. Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein. Clin. Chem. 2002, 48:1021-1027.
22. Portel-Gomes G.M., Grimelius L., Johansson H., Wilander E., Stridsberg M. Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies. Am. J. Surg. Pathol. 2001, 25:1261-1267.
23. Ranno S., Motta M., Rampello E., Risino C., Bennati E., Malaguarnera M. The chromogranin-A (CgA) in prostate cancer. Arch. Gerontol. Geriatr. 2006, 43:117-126.
24. Reubi J.C., Waser B., Liu Q., Laissue J.A., Schonbrunn A. Subcellular distribution of somatostatin SST-2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J. Clin. Endocrinol. Metab. 2000, 85:3882-3891.
25. Reubi J.C., Waser B., Schaer J.C., Laissue J.A. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 2001, 28:836-846.
26. Roskams T., Willems M., Campos R.V., Drucker D.J., Yap S.H., Desmet V.J. Parathyroid hormone-related peptide expression in primary and metastatic liver tumours. Histopathology 1993, 23:519-525.
27. Sherman M. Hepatocellular carcinoma. Gastroenterologist 1995, 3:55-66.
28. Shimizu A., Shiraki K., Ito T., Sugimoto K., Sakai T., Ohmori S., Murata K., Takase K., Tameda Y., Nakano T. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepato-cellular carcinoma in patients with cirrhosis. Int. J. Mol. Med. 2002, 9:245-250.
29. Shinagawa T., Ohto M., Kimura K., Tsunetomi S., Morita M., Saisho H., Tsuchiya Y., Saotome N., Karasawa E., Miki M., Ueno T., Okuda K. Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the utility of real-time ultrasonography. A study in 51 patients. Gastroenterology 1984, 86:495-502.
30. Szende B., Horvath A., Bokonyi G., Keri G. Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma. Br. J. Cancer. 2003, 88:132-136.
31. Taupenot L., Harper K.L., O'Connor D.T. The chromogranin-secretogranin family. N. Engl. J. Med. 2003, 348:1134-1149.
32. Trevisani F., D'Intino P.E., Morselli-Labate A.M., Mazzella G., Accogli E., Caraceni P., Domenicali M., De Notariis S., Roda E., Bernardi M. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol. 2001, 34:603-605.
33. Tropea F., Baldari S., Restifo G., Fiorillo M.T., Surace P., Herberg A. Evaluation of chromogranin A expression in patients with non-neuroendocrine tumours. Clin. Drug Invest. 2006, 26:715-722.
34. Tsai T.J., Chau G.Y., Lui W.Y., Tsay S.H., King K.L., Loong C.C., Hsia C.Y., Wu C.W. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000, 127:603-608.
35. Wang C.S., Lin C.L., Lee H.C., Chen K.Y., Chiang M.F., Chen H.S., Lin T.J., Liao L.Y. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J. Gastroenterol. 2005, 11:6115-6119.
36. Watkinson A., Dockray G.J. Functional control of chromogranin A and B concentrations in the body of the rat stomach. Regul. Pept. 1992, 40:51-61.
37. Weckbecker G., Raulf F., Stolz B., Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol. Ther. 1993, 60:245-264.
38. Weitz I.C., Liebman H.A. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993, 18:990-997.
39. Wiedenmann B., Huttner W.B. Synaptophysin and chromogranins/secreto-granins-widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows. Arch. B. Cell. Pathol. Incl. Mol. Pathol. 1989, 58:95-121.
40. Wilander E., Lundqvist M., Oberg K. Gastrointestinal carcinoid tumours. Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects. Progr. Histochem. Cytochem. 1989, 19:1-88.
41. Wurmbach E., Chen Y.B., Khitrov G., Zhang W., Roayaie S., Schwartz M., Fiel I., Thung S., Mazzaferro V., Bruix J., Bottinger E., Friedman S., Waxman S., Llovet J.M. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007, 45:938-947.
42. Zhao M., Laissue J.A., Zimmermann A. Neuroendocrine" differentiation in hepatocellular carcinomas (HCCs): immunohistochemical reactivity is related to distinct tumor cell types, but not to tumor grade. Histol. Histopathol. 1993, 8:617-626.